Hepatitis A Clinical Trial
Official title:
The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A
This study is a randomized, placebo controlled, double-blinded clinical trial, which included 50 children with hepatitis A. They were of both sexes and their age ranged from 2 to 18 years. The patients were randomly assigned into one of two groups; each consisted of 25 children. Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks, whereas patients of the placebo group (group 2) took placebo in the form of molasses. The main outcome measure was the recovery time defined as the number of days from the start of the intervention to subsidence of symptoms and signs of hepatitis and return of liver transaminases to their normal levels.
This study is a randomized, placebo controlled double-blinded clinical trial, which was
conducted at the Children's Hospital of Ain Shams university during the period from November
2013 to May 2014. Eligible patients were previously healthy children of both sexes, aged 2
to 18 years, who developed manifestations of acute hepatitis. Patients with diabetes
mellitus (DM), chronic liver diseases, autoimmune disorders, renal disorders, neurologic
diseases or malignancy were excluded from the study. Eighty nine eligible patients were
recruited from the outpatient Clinic of the Children's Hospital of Ain Shams university and
were subjected to history taking, physical examination and laboratory investigations in the
form of serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum
gamma gultamyltransferase (GGT), serum bilirubin (total and direct) and assay for Hepatitis
A Virus IgM (HAV IgM). Only patients who had positive HAV IgM were candidates for this
study. They were seventy six patients who were randomly assigned following simple
randomisation procedure (computerized random numbers) to 1 of 2 groups with a 1:1 allocation
ratio.
During the study, a total of twenty six patients were excluded; nine patients stopped the
trial because they refused to repeat blood sampling for investigations, six patients were
not compliant to honey intake and ten patients lost follow up. Fifty patients, thus
completed the study protocol and were included in the final analysis.
Assuming the mean duration of the acute illness is 6 weeks and the mean (±SD) duration of
acute illness in the intervention group is 4 (±2), a total sample size of 42 patients (21
per group) is required to have a statistical power of 90% (alpha=0. 05). Post- hoc test was
used for power calculation.
Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day
(with a maximum dose of 150 ml/day) for four weeks. The dose of honey was empirical.
Each patient in the placebo group (group 2) took 5 ml molasses/kg/day; with a maximum of
150ml/day. Molasses is a honey-like substance made when cane sugar is processed. It contains
no fat and is composed mainly of sucrose, besides some fructose and glucose.
The main outcome measure was the recovery time defined as the number of days from the start
of the intervention to subsidence of symptoms and signs of hepatitis and return of liver
transaminases to their normal levels. The main symptoms and signs of hepatitis A are fever,
anorexia, nausea, vomiting, abdominal pain, dark urine, clay-colored stools and jaundice.
Physical examination focused on general condition, vital data, jaundice, hepatosplenomegaly
and ascites. The laboratory work up consisted of measurements of ALT, AST and GGT by kinetic
method, measurement of total and direct bilirubin levels by colorimetric method, and assay
of Anti-HAV IgM by ELISA.
Clinical and laboratory evaluation of each patient was done at baseline (0), 2nd week and
4th week (endpoint).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT01949857 -
The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
|
Phase 4 | |
Completed |
NCT00313950 -
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
|
Phase 4 | |
Completed |
NCT00139139 -
A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A
|
N/A | |
Completed |
NCT00197171 -
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine
|
Phase 3 | |
Completed |
NCT00139113 -
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
|
Phase 4 | |
Completed |
NCT03312699 -
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
|
Phase 1 | |
Completed |
NCT03855176 -
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
|
Phase 4 | |
Completed |
NCT00197002 -
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
|
Phase 3 | |
Withdrawn |
NCT02605538 -
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
|
N/A | |
Completed |
NCT04638335 -
What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years
|
||
Completed |
NCT00197015 -
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
|
Phase 3 | |
Active, not recruiting |
NCT06058416 -
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
|
Phase 4 | |
Completed |
NCT01453348 -
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT01865968 -
Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults
|
Phase 4 | |
Completed |
NCT02002065 -
The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children
|
N/A | |
Terminated |
NCT00119743 -
A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
|
Phase 3 | |
Completed |
NCT01000324 -
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
|
Phase 4 | |
Completed |
NCT00289731 -
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
|
Phase 4 | |
Completed |
NCT02601040 -
Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
|
Phase 4 |